Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina.
Phase 4
- Conditions
- Unstable Angina
- Interventions
- Drug: Anti-Platelet DrugsDrug: Lipid Regulating DrugsDrug: Coronary Vasodilator
- Registration Number
- NCT03179618
- Lead Sponsor
- Jun Li
- Brief Summary
This study evaluates the clinical efficacy of Xuefu Zhuyu Decoction in the treatment of unstable angina pectoris. All of the patients will be divided into 2 arms randomly. One of the arms will be treated by conventional western medicine, the other one will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
- Detailed Description
Xuefu Zhuyu Decoction has the function of activating qi and promoting blood circulation, which will be used to treat patients with qi stagnation and blood stasis syndrome.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Participants diagnosed with coronary heart disease through coronary angiography or coronary CTA;
Patients have at least one of these symptoms:
- The stability of the nature of angina pectoris changes, that is, frequent attacks of angina pectoris, serious degree and prolonged duration;
- Angina pectoris during rest;
- The recent occurrence of angina pectoris caused by mild physical activity in the last month.
Exclusion Criteria
- Patients diagnosed with stable angina; Patients with acute myocardial infarction; Chest pain caused by congenital heart disease, valvular heart disease, severe neurosis or arrhythmia; The heart function grade is III or IV; Patients with acute cerebral infarction; Patients complicated with other serious primary diseases; Patients with acute infection in recent 2 weeks; Uncontrolled hypertension (the resting blood pressure >160/95mmHg within one week); Diabetics emerged with serious diabetic complications; Patients can't finish the questionnaire due to abnormal mental and nervous or mental disorders; Pregnant or lactating women.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Qi stagnation and blood stasis Coronary Vasodilator Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine. Conventional western medicine Coronary Vasodilator Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc. Qi stagnation and blood stasis Anti-Platelet Drugs Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine. Qi stagnation and blood stasis Xuefu Zhuyu Decoction Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine. Conventional western medicine Lipid Regulating Drugs Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc. Qi stagnation and blood stasis Lipid Regulating Drugs Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine. Conventional western medicine Anti-Platelet Drugs Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
- Primary Outcome Measures
Name Time Method Mortality Six months after drug intervention Death caused by cardiovascular disease
- Secondary Outcome Measures
Name Time Method The incidence of myocardial infarction or heart failure Six months after drug intervention Treadmill exercise test At baseline and 4 weeks after drug intervention The result will be positive or negative
Myocardial enzymes At baseline and 4 weeks after drug intervention The unit is mmol/L
3. Blood lipid The unit is mmol/L. Blood lipid At baseline and 4 weeks after drug intervention 3. Blood lipid The unit is mmol/L. 3. Blood lipid The unit is mmol/L. The unit is mmol/L